NYMOZARFEX
Live / Allowed — Fourth extension granted (statement of use) (as of 03 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 22 Jan 2024 filing date already counts against anyone who files later.
Record
- Serial number
- 98369282
- Mark type
- Word mark
- Filed
- 22 Jan 2024
- Published for opposition
- 09 Jul 2024
- Attorney of record
- Patrick J. Jennings
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of benign prostatic hyperplasia and prostate cancer
Owner
- Nymox Pharmaceutical Corporation, Nassau, BS
- Nymox Pharmaceutical Corporation, Nassau, BS
Prosecution history
- 04 Sept 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Sept 2026 — SOU EXTENSION 4 GRANTED
- 03 Sept 2026 — SOU EXTENSION 4 FILED
- 03 Sept 2026 — SOU TEAS EXTENSION RECEIVED
- 04 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2026 — SOU EXTENSION 3 GRANTED
- 03 Mar 2026 — SOU EXTENSION 3 FILED
- 03 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 28 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Jan 2026 — SOU EXTENSION 2 GRANTED
- 02 Sept 2025 — SOU EXTENSION 2 FILED
- 26 Jan 2026 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 08 Dec 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 08 Dec 2025 — NOTICE OF REVIVAL - E-MAILED
- 08 Dec 2025 — PETITION TO REVIVE-GRANTED